Mid-Regional Proadrenomedullin and Mid-Regional Proatrial Natriuretic Peptide Clearance Predicts Poor Outcomes Better Than Single Baseline Measurements in Critically Ill Patients With Pneumonia: A Retrospective Cohort Study.
apache iv
biomarkers
mr-proadm
mr-proanp
pneumonia
sofa
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
28 May 2021
28 May 2021
Historique:
entrez:
5
7
2021
pubmed:
6
7
2021
medline:
6
7
2021
Statut:
epublish
Résumé
Background We assessed the ability of baseline and serial measurements of mid-regional proadrenomedullin (MR-proADM) and mid-regional proatrial natriuretic peptide (MR-proANP) to predict 28-day mortality in critically ill patients with pneumonia compared with Acute Physiological and Chronic Health Evaluation IV (APACHE IV) model and Sequential Organ Failure Assessment (SOFA) score. Methodology Biomarkers were collected for the first five days in this retrospective observational cohort study. Biomarker clearance (as a percentage) was presented as biomarker decline in five days. We investigated the relationship between biomarkers and mortality in a multivariable Cox regression model. APACHE IV and SOFA were calculated after 24 hours from intensive care unit admission. Results In 153 critically ill patients with pneumonia, 28-day mortality was 26.8%. Values of baseline MR-proADM, MR-proANP, and APACHE IV were significantly higher in 28-day nonsurvivors, but not significantly different for SOFA score. Baseline MR-proADM and MR-proANP, APACHE IV, and SOFA had a low area under the curve in receiver operating characteristics (ROC) curves. No optimal cut-off points could be calculated. Biomarkers and severity scores were divided into tertiles. The highest tertiles baseline MR-proADM and MR-proANP were not significant predictors for 28-day mortality in a multivariable model with age and APACHE IV. SOFA was not a significant predictor in univariable analysis. Clearances of MR-proADM and MR-proANP were significantly higher in 28-day survivors. MR-proADM and MR-proANP clearances had similar low accuracy to identify nonsurvivors in ROC curves and were divided into tertiles. Low clearances of MR-proADM and MR-proANP (first tertiles) were significant predictors for 28-day mortality (hazard ratio [HR]: 2.38; 95% confidence interval [CI]: 1.21-4.70; p = 0.013 and HR: 2.27; 95% CI: 1.16-4.46; p = 0.017) in a model with age and APACHE IV. Conclusions MR-proADM and MR-proANP clearance performed better in predicting 28-day mortality in a model with age and APACHE IV compared with single baseline measurements in a mixed population of critically ill with pneumonia.
Identifiants
pubmed: 34221750
doi: 10.7759/cureus.15285
pmc: PMC8237920
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e15285Informations de copyright
Copyright © 2021, Van Oers et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Ann Transl Med. 2016 Sep;4(17):329
pubmed: 27713887
Clin Chem Lab Med. 2019 Mar 26;57(4):549-555
pubmed: 30157027
Clin Chem. 2004 Jan;50(1):234-6
pubmed: 14709661
Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72
pubmed: 17278083
Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416
pubmed: 15699079
Intensive Care Med. 2007 Apr;33(4):703-10
pubmed: 17318497
Crit Care. 2006;10(3):R96
pubmed: 16805922
Crit Care Med. 2014 Dec;42(12):2500-7
pubmed: 25083975
Eur Respir J. 2011 Mar;37(3):595-603
pubmed: 20530040
Peptides. 2004 Aug;25(8):1369-72
pubmed: 15350706
Am J Infect Control. 2008 Jun;36(5):309-32
pubmed: 18538699
Intensive Care Med. 2013 Nov;39(11):1945-52
pubmed: 23949703
Intensive Care Med. 2009 Mar;35(3):430-8
pubmed: 19066850
Am J Kidney Dis. 2005 Oct;46(4):610-20
pubmed: 16183415
N Engl J Med. 2014 Feb 6;370(6):543-51
pubmed: 24499212
Crit Care. 2005 Feb;9(1):R37-45
pubmed: 15693965
PLoS Med. 2007 Oct 16;4(10):e296
pubmed: 17941714
Lancet Infect Dis. 2016 Jul;16(7):819-827
pubmed: 26947523
BMC Infect Dis. 2011 May 03;11:112
pubmed: 21539743
J Card Fail. 2007 Feb;13(1):42-9
pubmed: 17339002
Am J Respir Crit Care Med. 2010 Dec 1;182(11):1426-34
pubmed: 20639437
Crit Care. 2019 Jul 15;23(1):255
pubmed: 31307526
Crit Care. 2010;14(3):R106
pubmed: 20529344
N Engl J Med. 2014 Oct 23;371(17):1619-28
pubmed: 25337751
Crit Care. 2010;14(2):207
pubmed: 20392287